IASLC Thoracic Oncology, 2nd Edition
Global experts, in conjunction with the International Association for the Study of Lung Cancer, bring you up to date with today’s best approaches to lung cancer diagnosis, treatment, and follow-up. IASLC Thoracic Oncology, 2nd Edition, keeps you abreast of the entire scope of this fast-changing field, from epidemiology to diagnosis to treatment to advocacy. Written in a straightforward, practical style for the busy clinician, this comprehensive, multidisciplinary title is a must-have for anyone involved in the care of patients with lung cancer and other thoracic malignancies.
Global experts, in conjunction with the International Association for the Study of Lung Cancer, bring you up to date with today’s best approaches to lung cancer diagnosis, treatment, and follow-up. IASLC Thoracic Oncology, 2nd Edition, keeps you abreast of the entire scope of this fast-changing field, from epidemiology to diagnosis to treatment to advocacy. Written in a straightforward, practical style for the busy clinician, this comprehensive, multidisciplinary title is a must-have for anyone involved in the care of patients with lung cancer and other thoracic malignancies.
New to this edition
- Includes new content on molecular testing, immunotherapy, early detection, staging and the IASLC staging system, surgical resection for stage I and stage II lung cancer, and stem cells in lung cancer.
- Features a new full-color design throughout, as well as updated diagnostic algorithms.
- Expert Consult™ eBook version included with purchase. This enhanced eBook experience allows you to search all of the text, figures, Q&As, and references from the book on a variety of devices.
Key Features
- Offers practical, relevant coverage of basic science, epidemiology, pulmonology, medical and radiation oncology, surgery, pathology, palliative care, nursing, and advocacy.
- Provides authoritative guidance from the IASLC – the only global organization dedicated to the study of lung cancer.
Author Information
| ISBN Number | 9780323523578 |
|---|---|
| Description Author List | By Harvey Pass, MD, Stephen E. Banner Professor of Thoracic Oncology, Vice Chair of Research NYUHC, Departments of Cardiothoracic Surgery, New York University Langone Medical Center, New York, New York; David Ball, MD, FRANZCR, Director, Lung Cancer Stream, Victorian Comprehensive Cancer Centre, Parkville Professional Fellow, the Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia and Giorgio Scagliotti, MD, PhD, Professor of Medical Oncology, Head of Department of Oncology at S. Luigi Hospital, University of Turin, Orbassano (Torino), Italy |
| Copyright Year | 2018 |
| Edition Number | 2 |
| Format | Book |
| Trim | 216w x 276h (8.50" x 10.875") |
| Imprint | Elsevier |
| Page Count | 686 |
| Publication Date | 20 Jun 2017 |
| Stock Status | Please allow 3-4 weeks for delivery |
eBooks : Built for busy schedules & tailored for your goals.
Affordable knowledge, built for you
Get the resources you need-often at a lower cost than print. Quality content designed to support your goals, without stretching your budget.
Seamless access wherever you are
Always in sync
Tools the make learning stick
Your eBook is ready whenever you are!
1. Check your email for your access code.
2. Sign into or create your VitalSource account and redeem your code.
3. Open your eBook - ready whenever you are!
FAQ
The access code for your new eBook will be sent in your order confirmation email. Your code can also be accessed in your My Account section on the Elsevier webshop. If you do not receive your code within a few minutes, please check your spam folder.
Step-by-step guidance on how to download Bookshelf and also redeem your code can be found here.
The access code for your new eBook does not expire. However, we always suggest redeeming immediately after purchase to start experiencing the benefits of and insights from your purchase. Important to note - the code provided is a single use code and only valid for the edition you purchase. It does not provide access to past nor future editions of the title.
You will have unlimited access to your eBook on the device to which it was downloaded.
Discover the various learning features that our eBooks offer on the Bookshelf® Reader! For example, you can highlight different text passages, create notes and flashcards, have the text read to you, etc. Particularly practical: You can also use your eBooks offline. More information on the learning functions can be found on the Vitalsource page.
Quality is our top priority. That's why we collaborate with the leading eBook reader provider VitalSource. VitalSource has its own eBook reader Bookshelf®, which you can easily download. This reader is very user-friendly and offers more features than other standard readers. For example, you can highlight different text passages, create notes and flashcards, have the text read to you, etc. Particularly practical: You can also use your eBooks offline. More information can be found on the Vitalsource page.
Elsevier offers its eBooks in ePub format, as we believe this format is best suited to display our content ideally on as many devices as possible.
You can return your eBook within 13 days of purchase. eBooks that have been partially printed or flipped through more than 15% are excluded from returns.
Any questions ?
Top Picks from Our Community
E-Book
E-Book
E-Book
E-Book
E-Book
E-Book
E-Book
E-Book
E-Book
E-Book
E-Book
E-Book
E-Book
E-Book
E-Book
E-Book
E-Book
E-Book
E-Book
E-Book
E-Book
Section 1: Lung Cancer Control and Epidemiology
1. Classical Epidemiology
2. Tobacco Control and Primary Prevention
3. Tobacco Cessation
4. Non-Smoking Related Lung Cancer
5. Gender-Related Differences in Lung Cancer
6. Genetic Susceptibility to Lung Cancer
7. Early Detection and Radiologic Screening
8. Preclinical Biomarkers for The Early Detection of Lung Cancer
9. Chemoprevention of Lung Cancer: Present and Developing Technologies
Section 2: Lung Cancer Molecular Carcinogenesis
10. Copy Number Abnormalities and Gene Rearrangements in Lung Cancer: Present and Developing Technologies
11. Mutational Events in Lung Cancer: Present and Developing Technologies
12. Epigenetic Events, Alterations, and Remodeling in Lung Cancer: Present and Developing Technologies
13. Stem Cells and Lung Cancer: In Vitro and In Vivo Studies
14. Microenvironment and Lung Cancer
15. MicroRNAs as Biomarkers for Lung Cancer
Section 3: Immunology
16. Humoral and Cellular Immune Dysregulation and Lung Cancer
Section 4: Pathology
17. Classic Anatomic Pathology and Lung Cancer
18. Molecular Testing and Lung Cancer
19. Management of the Small Biopsy in the Molecular Er
Section 5: Clinical and Radiologic Presentation of Lung Cancer
20. Clinical Presentation
21. Conventional Imaging Lung Cancer
22. PET Imaging of Lung Cancer
Section 6: Diagnosis and Staging of Lung Cancer
23. Diagnostic Work-Up of Suspected Lung Cancer
24. Surgical Staging of the Mediastinum including Mediastinoscopy and Thoracoscopy, Preoperative and Intraoperative
25. The 8th Edition of the Tumor, Node and Metastasis Classification of Lung Cancer
Section 7: Surgical Management of Lung Cancer
26. Preoperative Functional Evaluation of the Surgical Candidate
27. Results of Video Assisted Techniques for Resection of Lung Cancer
28. Results of Robotic Techniques for Resection of Lung Cancer
29. Extent of Surgical Resection for Stage I and II Lung Cancer
30. Extended Resections for Lung Cancer: Chest Wall and Pancoast Tumors
31. Extended Resections for Lung Cancer: Broncho/Vascular Sleeve Resections
32. Multiple Nodules: Management of the Patient with Synchronous or Metachronous Lung Cancers
33. Surgical Management of the Marginally Resectable Patient
Section 8: Radiotherapeutic Management of Lung Cancer
34. Technical Requirements for Lung Cancer Radiotherapy
35. Radiobiology of Lung Cancer
36. Patient Selection for Radiotherapy
37. Stage I Non-Small Cell Lung Cancer and Oligometastatic Disease
38. Ablation Options for Localized Lung Cancer
39. Radiotherapy for Locally Advanced Non-Small Cell Lung Cancer, including Combined Modality
40. Radiotherapy in the Management of Small Cell Lung Cancer: Thoracic Radiotherapy, Prophylactic Cranial Irradiation
41. Palliative Radiotherapy for Lung Cancer: Locoregional and Metastatic
42. Acute and Late Toxicities of Thoracic Radiotherapy: Pulmonary, Esophagus, Heart
43. Treatment-Related Neurotoxicity, Medical and Radiation Therapy
Section 9: Chemotherapy and Targeted Agents for Lung Cancer
44. Front-Line Systemic Options in Non-Small Cell Lung Cancer
45. Systemic Options in Second Line and Beyond
46. Maintenance Therapy in NSCLC
47. Pharmacogenomics and Lung Cancer
48. New Targetable Pathways in Lung Cancer
49. Management of Toxicities of Targeted Therapies
50. Immunotherapy and Lung Cancer
51. Systemic Therapy in Early-Stage NSCLC
52. Treatment of Small-Cell Lung Cancer
Section 10: Other Thoracic Malignancies
53. Malignant Mesothelioma
54. Mediastinal Tumors
55. Neuroendocrine Tumors of the Lung Other than SCLC
56. Thymic Cancer/Thymoma
Section 11: Symptom Management and Complications
57. Lung Cancer Emergencies
58. Role of Palliative Care in Lung Cancer
Section 12: Clinical Trials
59. Methodology of Clinical Trials in Lung Cancer
60. How to Promote and Organize Clinical Research in Lung Cancer
Section 13: Thoracic Oncology Advocacy
61. Role of Advocacy Groups in Lung Cancer
62. Health Services Research in Lung Cancer
Appendix
63. Appendix: Diagnostic Algorithms
"Overall, this is an outstanding resource that everyone interested in this subject must have…. The main objective of this book and the well-thought-out content sets it apart from any other book in the same space." Reviewed by Ravi Salgia, MD, PhD (City of Hope) Doody's Score: 98, 5 Stars!
